Bottom line
Is SURI a good fund? The bottom line
SURI is an actively managed large blend ETF from Simplify Exchange Traded.
Annual fees run 2.59% — about $259 a year on every $10,000 invested, more expensive than 97% of large blend funds we track.
It returned +25.1% over one year (as of Dec 31, 2025, per its prospectus).
With $77.3 million in net assets and 39 holdings, its largest position is United States Of America - Bureau Of The Public Debt (76.8%) and the top 10 make up 155.1% of the portfolio.
What to watch
- Expensive for its category (2.59%)
- Concentrated: top 10 holdings are 155.1% of assets
Updated Nov 19, 2026
What SURI invests in
Investment Objective: The Simplify Propel Opportunities ETF (the Fund or SURI) seeks long-term capital appreciation.
Principal Investment Strategies: The Fund is an actively managed exchange-traded fund (ETF). The Funds investment adviser Simplify Asset Management Inc. (the Adviser) collaborates with the Funds sub-adviser, Propel Bio Management, LLC (the Sub-Adviser), to seek to achieve the Funds investment objective. The Fund concentrates its investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. Each of these industries are commonly categorized within the healthcare sector because they share similar economic features and regulatory constraints. The Fund also may invest in securities of issuers engaged in energy-related endeavors such as the production, generation, and sale of energy resources. The Sub-Adviser employs an actively managed opportunistic…
From the fund's prospectus (filed Oct 28, 2026).
SURI performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| SURI | +25.1% | — | — |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What SURI costs
On a $10,000 investment, SURI's 2.59% expense ratio costs about $259 a year. The prospectus estimates $3,152 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
SURI top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | United States Of America - Bureau Of The Public Debt | 76.77% |
| 2 | Plains Gp Holdings Lp PAGP | 39.97% |
| 3 | Achieve Life Sciences Inc ACHV | 12.11% |
| 4 | Milestone Pharmaceuticals Inc MIST | 5.81% |
| 5 | Achieve Life Sciences Inc | 4.42% |
| 6 | Delcath Systems Inc DCTH | 4.26% |
| 7 | Phathom Pharmaceuticals Inc PHAT | 3.50% |
| 8 | Corcept Therapeutics Inc CORT | 2.98% |
| 9 | Abeona Therapeutics Inc ABEO | 2.76% |
| 10 | Celldex Therapeutics Inc CLDX | 2.56% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 155.1% of the fund. See all top 25 holdings and asset mix →